NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
14.30
-0.50 (-3.38%)
Jan 31, 2025, 4:00 PM EST - Market closed
NeoGenomics Revenue
NeoGenomics had revenue of $167.82M in the quarter ending September 30, 2024, with 10.44% growth. This brings the company's revenue in the last twelve months to $644.12M, up 12.06% year-over-year. In the year 2023, NeoGenomics had annual revenue of $591.64M with 16.07% growth.
Revenue (ttm)
$644.12M
Revenue Growth
+12.06%
P/S Ratio
2.81
Revenue / Employee
$306,723
Employees
2,100
Market Cap
1.84B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 591.64M | 81.92M | 16.07% |
Dec 31, 2022 | 509.73M | 25.40M | 5.24% |
Dec 31, 2021 | 484.33M | 39.88M | 8.97% |
Dec 31, 2020 | 444.45M | 35.62M | 8.71% |
Dec 31, 2019 | 408.83M | 132.09M | 47.73% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
NEO News
- 3 days ago - NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025 - Business Wire
- 17 days ago - NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan - Business Wire
- 22 days ago - NeoGenomics Announces Chief Executive Officer Succession - Business Wire
- 26 days ago - NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma - Business Wire
- 7 weeks ago - NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting - Business Wire
- 2 months ago - ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research - Business Wire
- 2 months ago - NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment - Business Wire